Literature DB >> 26974499

Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users.

Mariska Bot1, Yuri Milaneschi2, Brenda W J H Penninx2, Madeleine L Drent3.   

Abstract

It has been postulated that many peripheral and (neuro)biological systems are involved in psychiatric disorders such as depression. Some studies found associations of depression and antidepressant treatment with insulin-like growth factor 1 (IGF-I) - a pleiotropic hormone affecting neuronal growth, survival and plasticity - but evidence is mixed. We therefore studied whether depressive and anxiety disorders were associated with plasma IGF-I, and explored the role of antidepressant medication in this association in a large observational study. The sample consisted of 2714 participants enrolled in The Netherlands Study of Depression and Anxiety, classified as healthy controls (n=602), antidepressant users (76 remitted and 571 with current depressive and/or anxiety disorder(s), n=647), persons having remitted depressive and/or anxiety disorder(s) without antidepressant use (n=502), and persons having current depressive and/or anxiety disorder(s) without antidepressant use (n=963). Associations with IGF-I concentrations were studied and adjusted for socio-demographic, health, and lifestyle variables. Relative to healthy controls, antidepressant-free individuals with current disorders had significantly higher IGF-I levels (Cohen's d=0.08, p=0.006), whereas antidepressant-free individuals with remitted disorders had a trend towards higher IGF-I levels (d=0.06, p=0.09). Associations were evident for depressive and for anxiety disorders. In contrast, antidepressant users had significantly lower IGF-I levels compared to healthy controls (d=-0.08, p=0.028). Our findings suggests that antidepressant medication use modifies the association between depressive/anxiety disorders and plasma IGF-I. These results corroborate with findings of some previous small-scale case-control and intervention studies. The higher IGF-I levels related to depression and anxiety might point to a compensatory mechanism to counterbalance the impaired neurogenesis, although future studies are needed to support this hypothesis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antidepressant medication; Anxiety disorders; Cohort; Depressive disorders; Insulin-like growth factor-I; Neurotrophic factor

Mesh:

Substances:

Year:  2016        PMID: 26974499     DOI: 10.1016/j.psyneuen.2016.02.028

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  9 in total

1.  Central IGF-1 protects against features of cognitive and sensorimotor decline with aging in male mice.

Authors:  Gabriela E Farias Quipildor; Kai Mao; Zunju Hu; Ardijana Novaj; Min-Hui Cui; Maria Gulinello; Craig A Branch; Sriram Gubbi; Khushbu Patel; Douglas R Moellering; Stefano Tarantini; Tamas Kiss; Andriy Yabluchanskiy; Zoltan Ungvari; William E Sonntag; Derek M Huffman
Journal:  Geroscience       Date:  2019-05-10       Impact factor: 7.713

2.  The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy.

Authors:  Alexandra S Troyan; Oleg A Levada
Journal:  Front Psychiatry       Date:  2020-08-13       Impact factor: 4.157

3.  The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Mahmoud S Abdallah; Esraa M Mosalam; Abdel-Aziz A Zidan; Khaled S Elattar; Shimaa A Zaki; Ahmed N Ramadan; Abla M Ebeid
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

Review 4.  Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.

Authors:  Oleg A Levada; Alexandra S Troyan
Journal:  Ann Gen Psychiatry       Date:  2017-10-26       Impact factor: 3.455

5.  Circulating insulin-like growth factor I modulates mood and is a biomarker of vulnerability to stress: from mouse to man.

Authors:  A Santi; M Bot; A Aleman; B W J H Penninx; I Torres Aleman
Journal:  Transl Psychiatry       Date:  2018-08-01       Impact factor: 6.222

6.  Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits.

Authors:  Sara G Higarza; Silvia Arboleya; Miguel Gueimonde; Eneritz Gómez-Lázaro; Jorge L Arias; Natalia Arias
Journal:  PLoS One       Date:  2019-09-20       Impact factor: 3.240

Review 7.  Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression.

Authors:  Marion J F Levy; Fabien Boulle; Harry W Steinbusch; Daniël L A van den Hove; Gunter Kenis; Laurence Lanfumey
Journal:  Psychopharmacology (Berl)       Date:  2018-06-30       Impact factor: 4.530

8.  Effects of Moxibustion on the Levels of Insulin-Like Growth Factor 1: A Pilot Study.

Authors:  Jaung-Geng Lin; Shinn-Zong Lin; Lih-Hwa Lin; Chun-Chang Wu; Wan-Ting Tsai; Horng-Jyh Harn; Li-Hui Su; Wen-Yu Ho; Che-Jui Hsieh; Tsung-Jung Ho
Journal:  Cell Transplant       Date:  2018-04-25       Impact factor: 4.064

9.  Insulin-like growth factor I mitigates post-traumatic stress by inhibiting AMP-kinase in orexin neurons.

Authors:  M Estrella Fernández de Sevilla; Jaime Pignatelli; Jonathan A Zegarra-Valdivia; Pablo Mendez; Angel Nuñez; Ignacio Torres Alemán
Journal:  Mol Psychiatry       Date:  2022-02-03       Impact factor: 13.437

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.